FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	D.C.	20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burde	en								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Ferguson Matthew (Last) (First) (Middle) C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370				3. Da 03/0	Issuer Name and Ticker or Trading Symbol AZIYO BIOLOGICS, INC. [AYZO] Date of Earliest Transaction (Month/Day/Year) 03/08/2021							elationship of Reporting Person(s) to Issuer ck all applicable) Director 10% Owner Officer (give title Other (specify below) CHIEF FINANCIAL OFFICER				ecify
(Street) SILVER SPRING,	MD		9904	4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	ndividual or Joint/Group Filing (Check Applicable) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State	<u> </u>	e I - Non-Deri	vative	Sec	uritios	Λ.ς.	nuired Die	enosad o	f or Bene	ficially	Owned				
1. Title of Security (Instr. 3)		2. Tran Date	saction 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction	4. Securit	les Acquired (A) or Of (D) (Instr. 3, 4 and 5		5. Amount of Securities F Beneficially (Form: Direct I (D) or Indirect E (I) (Instr. 4)		Nature of direct eneficial wnership nstr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of 2. 3. Transaction Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year)		4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and A of Securities Underlying D Security (Ins 4)		Amount S Derivative	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Own Forr Dire or In (I) (II	ership 1: ct (D) direct nstr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
STOCK OPTION (RIGHT TO BUY)	\$14.53	03/08/2021		A		30,900		(1)	03/08/2031	CLASS A COMMON STOCK	30,900	\$0.00	30,900)	D	
RESTRICTED STOCK UNITS	(2)	03/08/2021		A		5,150		(3)	(3)	CLASS A COMMON STOCK	5,150	\$0.00	5,150		D	

Explanation of Responses:

- 1. This option vests as to 25% of the shares on March 8, 2022, and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2025.
- $2. \ Each \ restricted \ stock \ unit \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ Issuer \ Class \ A \ common \ stock.$
- 3. The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date.

/s/ Ronald Lloyd, Attorney-in-03/10/2021 fact for Matthew Ferguson

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.